Flossbach Von Storch Ag Bei Gene, Ltd. Transaction History

Flossbach Von Storch Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$121.11 - $216.05 $181,665 - $324,075	-1,500 Reduced 33.33%	3,000 $486,000
Q1 2022 May 11, 2022	SELL	$146.52 - $269.56 $146,520 - $269,560	-1,000 Reduced 18.18%	4,500 $849,000
Q4 2021 Feb 04, 2022	BUY	$248.56 - $389.34 $124,280 - $194,670	500 Added 10.0%	5,500 $1.49 Million
Q3 2021 Nov 04, 2021	BUY	$249.6 - $403.14 $1.25 Million - $2.02 Million	5,000 New	5,000 $1.82 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Flossbach Von Storch Ag, based on Form 13F filings with the SEC.

Stay updated on Flossbach Von Storch Ag with notifications on news.